4-day Plaque Accumulation Model Evaluating Compound Containing Gum
Lactea Therapeutics, LLC · with Indiana University · NCT06984744
Opens the official ClinicalTrials.gov record, with the study team’s contacts. Bored Studies doesn’t enroll anyone.
Key facts
- Compensation
- Not posted. Ask the study team before screening.
- Who can join
- Ages 18–65 · All sexes
- Healthy volunteers
- Accepted
- Study type
- Interventional · Not applicable
- Target enrollment
- 32
- US sites recruiting
- 1
- Study start
- June 23, 2025
- Record last updated
- August 27, 2025
Status re-checked against ClinicalTrials.gov within the last 12 hours.
What the study is about
This will be a single-blind, single-center, 3-way crossover, randomized controlled clinical trial with 3 treatment periods utilizing 32 subjects. (Fig 1, in protocol) Each treatment period will be 4 days (96 hours +/-3 hours) in accordance with the plaque accumulation model using one of the following treatment groups: an active compound MIIP-E2 gum (experimental regimen), an inactive compound gum (negative control regimen), and a no-gum (control regimen).
Being studied: MIIP-E2 containing gum; placebo gum without MIIP-E2
Conditions: Dental Plaque Accumulation
Eligibility criteria
Copied from the official record. The study team makes the final decision at screening.
Show full criteria
Inclusion Criteria
- Adult subjects between 18 and 65 years old
- Willing to read and sign the IRB-approved informed consent.
- Healthy, as determined by pertinent medical history at the study dentist's discretion.
- A minimum of 20 natural teeth (excluding third molars) with at least two scorable surfaces per tooth (teeth with full crowns, large/extensive restorations on the interproximal areas, and orthodontic bands will not be included in the tooth count)
- PLI of 2 or greater (Based on the Turesky modification of the Quigley and Hein Plaque Index) calculation based on a whole mouth plaque score.
- Willing to comply with the study procedures.
Exclusion Criteria
- Presence of any acute or chronic condition, organ system disease, or medication that, in the principal investigator's opinion, could compromise the subjects' ability to participate in the study.
- Gross oral pathologies, including caries, calculus, or soft tissue conditions that show evidence of chronic neglect.
- Evidence of acute periodontal conditions or periodontitis with pockets greater than 5 mm on more than one site
- Use of antibiotics 30 days prior to or during the study
- Requiring the need for antibiotic premedication prior to dental procedures
- Sensitivity to bovine products (lactoferrin) or any of the listed inactive ingredients
- Orthodontic appliances or any removable, except lingual bar retainers
- Self-reported pregnant, wanting to get pregnant, or breast-feeding female,
- Self-reported allergy to disclosing solution ingredients (red dye #28)
- Acute Temporomandibular Disorders (TMD)
- Subject who has participated in other studies (including non-medicinal studies) involving product(s) within 30 days before study screening.
- Subject who has previously been randomized in this study
- An employee of the study site directly involved with the study
Recruiting US locations
Oral Health Research Institute
Indianapolis, IN 46202
Site contact: Lorena Galvez · 317-274-8838 · logalvez@iu.edu
Study contacts (from the official record)
- Matthew Bender, PHD · 12406565322 · matt@agrilogicsgroup.com
- Lorena Galvez · 3172748838 · logalvez@iu.edu
Similar studies in Indiana
All healthy volunteers studies in Indiana →- RecruitingHealthy volunteersEarly Phase 1Overnight stay mentioned
Interaction of CYP2B6 Genotype and Efavirenz With Methadone and Tizanidine PK
Indiana University
- Location
- Indianapolis, IN
- Eligibility basics
- Ages 18–65
- RecruitingHealthy volunteersPhase 1
Ph 1a/1b Single Ascending Dose and Multiple Ascending Dose Study of ARQ-234
Arcutis Biotherapeutics, Inc.
- Location
- Plainfield, IN + 6 other US sites
- Eligibility basics
- Ages 18–65
- RecruitingHealthy volunteersPhase 1/Phase 2
Phase 1/2 Study of Respiratory Syncytial Virus and Human Metapneumovirus (RSV+HMPV) Vaccine Candidate in Adults 60 Years of Age and Older
Sanofi
- Location
- Indianapolis, IN + 49 other US sites
- Eligibility basics
- Ages 60+
- RecruitingHealthy volunteersPhase 1/Phase 2
Harmony-HHT: ATV-1601 in Participants With Hereditary Hemorrhagic Telangiectasia (HHT)
Atavistik Bio, Inc
- Location
- Indianapolis, IN + 5 other US sites
- Eligibility basics
- Ages 18+